Drug intelligence / Profile preview

Omegavue

Development stage: Unknown
Lead developer: Akrovis
Modality: Small Molecules
Administration: Oral

Overview

Omegavue is an oral dietary supplement marketed by Akrovis Pharmaceuticals, an Indian healthcare company specializing in generic and over-the-counter (OTC) products. Formulated as softgel capsules, Omegavue is positioned within the company's consumer healthcare portfolio, likely targeting nutritional support for ocular health or general wellness through the inclusion of omega-3 fatty acids. As a generic consumer product, it does not follow a traditional clinical development pipeline and is available for direct purchase in the Indian market.

Brand names: Omegavue
Other names: Omegavue softgel capsules

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)FFAR4 (Free fatty acid receptor 4)

Beyond the preview

Go deeper on Omegavue.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Omegavue.

Explore the full profile